Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 197 clinical trials
1 march 4  

This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …

  • 0 views
  • 19 Feb, 2024
  • 1 location
2 march edit9  

This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …

  • 0 views
  • 26 Sep, 2024
  • 1 location
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

  • 0 views
  • 19 Feb, 2024
  • 2 locations
4SCAR-T Therapy Post CD19-targeted Immunotherapy

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized …

  • 0 views
  • 19 Feb, 2024
  • 3 locations
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

immunochemotherapy
obinutuzumab
monoclonal antibodies
b-cell lymphoma
contraceptive use
  • 0 views
  • 19 Feb, 2024
  • 3 locations
TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia.

clpd-nk
lymphoproliferative disorder
hepatosplenomegaly
cytopenia
large granular lymphocytic leukemia
  • 0 views
  • 19 Feb, 2024
  • 9 locations
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

oxygen saturation
cellular therapy
induction chemotherapy
chronic lymphocytic leukemia
cell transplantation
  • 0 views
  • 19 Feb, 2024
  • 1 location
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce …

b-cell lymphoma
systemic disease
immediate hypersensitivity reaction
measurable disease
alt/ast
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

cancer, ovarian
b-cell lymphoma
solid tumors
small cell lung cancer
cancer
  • 0 views
  • 19 Feb, 2024
  • 4 locations